- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
CEA-Scan MoAb agent cleared in Europe
Immunomedics of Morris Plains, NJ, last week announced that ithas received clearance from the European Commission to marketits CEA-Scan colorectal cancer imaging agent in the 15 countriesof the European Union. The monoclonal-antibody-based agent
Immunomedics of Morris Plains, NJ, last week announced that it
has received clearance from the European Commission to market
its CEA-Scan colorectal cancer imaging agent in the 15 countries
of the European Union. The monoclonal-antibody-based agent received
U.S. clearance in June (SCAN 7/17/96). Mallinckrodt Medical of
St. Louis has marketing rights to CEA-Scan in both the U.S. and
Europe.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
